Trial Profile
A Phase 1, Single-Center, Open-label Study to Evaluate the Pharmacokinetics of PRN1008 in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Rilzabrutinib (Primary) ; Rilzabrutinib
- Indications Autoimmune disorders
- Focus Pharmacokinetics
- 06 Aug 2015 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry
- 19 Jun 2015 New trial record